Agrimonolide (AM), which is a derivative of isocoumarins, is found mainly in the herb Agrimonia pilosa Ledeb. This compound is highly lipophilic and readily crosses the blood–brain barrier. Interest has grown in the use of AM as a multitarget natural treatment for various diseases, such as cancer, inflammation, hepatic injury, myocardial damage, and diabetes mellitus. The potential mechanisms of these pharmacological effects have been clarified at cellular and molecular levels. AM shows no cytotoxicity over a range of concentrations in different types of cells, providing evidence for its good safety profile in vitro. These findings indicate that AM is a promising medicinal agent.
Parts |
Methods of Extraction and Isolation |
Yield |
Content |
Ref. |
---|
Physicochemical Properties |
Property Value |
Ref. |
|||||||
---|---|---|---|---|---|---|---|---|---|
Models | Concentrations or Doses of AM |
Mechanisms |
Ref. |
||||||
Fresh stems |
|||||||||
color/form |
8.6 kg of S. formosana is extracted with hot ethanol, and the water suspension of the ethanol extract is subjected to a liquid-liquid partition to obtain chloroform, n-butanol, and water subfractions, respectively. The chloroform subfraction is then fractionated by silica gel column chromatography. |
white powder 5.6 mg |
0.65 mg/kg |
[ |
|||||
anti-gastric cancer |
in vitro |
AGS cells |
40 µM, IC50 = 25.9 μM |
decrease the expression of Bcl-2; increase the expression of Bax; increase the level of phospho-ERK/ERK protein and the expression of phosphor-p38 protein; increase the activity of caspase-3; down-regulate the levels of the inactive pro-caspase-3, -8, and -9 proteins |
[6] |
||||
Fresh roots |
molecular weight 10 kg of A. pilosa |
||||||||
anti-ovarian cancer | is extracted with methanol, and the extract is shaken with diethyl ether. The soluble part is boiled several times with petroleum ether, and the residue is heated and extracted repeatedly with benzene. Finally, the precipitated crystals are recrystallized from benzene and then from methanol. |
314.3 g/moL 3000–4000 mg |
300–400 mg/kg |
[ |
in vitro28] [1] |
||||
A2780 and SKOV-3 cells |
40 µM |
Dried plant |
partition coefficient 50 kg of A. pilosa is extracted with 60% ethanol, and the 30% ethanol elution part of macroporous resin is separated by silica gel column chromatography, recrystallization, ODS column chromatography, Sephadex LH-20 gel column chromatography and preparative high-performance liquid chromatography. |
3.649 202 mg |
4.04 mg/kg |
[ |
|||
distribution coefficient |
1 |
||||||||
increase the cleavage of caspase-3 and -9; | increase the levels of ROS, total iron and ferrous ion, and down-regulate the levels of SLC7A11 and GPX4, thus inducing ferroptosis; |
Dried aerial parts |
13 kg of A. pilosa is extracted with methanol and the extract is suspended in water. The suspension is partitioned between hexane, ethyl acetate, and n-butanol. The ethyl acetate fraction is then fractionated by repeated silica gel column chromatography. |
43.7 mg |
3.36 mg/kg |
2.949 [11] |
|||
[ | 27] |
NA |
|||||||
acid dissociation constant |
Ethyl acetate fraction of methanol extract of A. pilosa is chromatographed repeatedly with silica gel columns and purified by preparative thin layer chromatography. |
8.10 ± 0.40 |
ADMET CYP2D6 |
0.356 6.5 mg |
[28] |
||||
0 |
NA |
[4] |
|||||||
Dried roots |
290 g of A. pilosa is extracted with hot water and the filtrated aqueous solution is partitioned with ethyl acetate and n-butanol, successively. The ethyl acetate soluble fraction is chromatographed by silica gel column repeatedly. |
44 mg |
151.7 mg/kg |
[8] |
|||||
Dried plant |
500 g of A. pilosa is extracted with 70% ethanol. The extract is then eluted with different concentrations of ethanol on the macroporous resin. The 50% ethanol eluted fractions is collected and used for subsequent high-speed counter-current chromatography separation. |
385.2 mg |
770.4 mg/kg |
[23] |
density | |||
1.293 g/cm3 |
|||
ADMET PPB |
/ |
[28] |
|
2 | |||
drug-likeness |
0.842 |
good |
Pharmacological Effects |
Levels |
||||
---|---|---|---|---|---|
direct inhibit tumor cell migration and invasion; | |||||
inhibit the protein levels of SCD1 | [ | 5] |
|||
in vivo |
SKOV-3 xenograft model (BALB/c mice) |
50 mg/kg |
down-regulate the expressions of Ki-67 and SCD1; lower the expressions of SCD1 mRNA and protein |
[5] |
|
melting point | |||||
175.5–176.5 °C |
[29] |
||||
boiling point |
581.1 °C at 760 mmHg |
[28] |
|||
refractive index |
1.611 |
[28] |
|||
flash point |
215.5 °C |
[28] |
|||
vapour pressure |
4.2E–14 mmHg at 25 °C |
[28] |
ADMET Properties |
Prediction Value |
Level |
||||
---|---|---|---|---|---|---|
ADMET absorption |
/ |
0 |
||||
ADMET BBB |
–0.241 |
2 |
||||
ADMET solubility |
–4.092 |
2 |
||||
ADMET hepatotoxicity |
||||||
anti-diabetic |
0.655 |
in vitro |
PANC-1 cell |
1 μM; 5 μM |
promote the expression of PDX-1 |
[22] |
in vitro |
/ |
IC50 = 37.4 μM |
inhibit α-glucosidase |
[11] |
||
in vitro |
Insulin-resistance HepG2 cell |
20 µM |
elevate the activity of GK, and increase the content of glycogen; lower the activities of PEPCK and G6Pase, and constrain the gluconeogensis |
[12] |
||
anti-oxidative and hepatoprotective |
in vitro |
HepG2 cell; rat primary hepatocytes |
EC50 = 88.2 μM; EC50 = 37.7 μM |
scavenge the free radical |
[8] |
|
in vitro |
HepG2 cell |
200 μM |
scavenge the free radical; activate Nrf2-driven pathways; activate ERK, JNK, and MAPK phosphorylation; inhibit p38 phosphorylation; elevate the activity of antioxidative enzymes |
[7] |
||
anti-inflammatory |
in vitro |
RAW 264.7 cells |
80 μM |
reduce the levels of IL-1β, IL-6, and TNF-α; attenuate the expression of iNOS and COX-2; inhibit the activation of JNK and p38 MAPKs; decrease the activation of JAK-STAT and NF-κB |
[4] |
|
myocardial protective |
in vitro |
H9c2 cell |
15 μM |
regulate the gene expression involved in mitochondrial function; decrease the levels of cleaved Caspase 3 and Bax; boost the level of Bcl2; prevent the rate of apoptosis and shield H9c2 cells from hypoxia-induced apoptosis; reduce ROS production and preserve the normal shape of mitochondria; regulate the functional proteins to enhance the mitochondrial activity |
[10] |
|
in vivo |
CLP rat model |
5 mg/kg |
attenuate myocardial injury by Akt signaling; suppress cardiac injury indicators, oxidative stress, and inflammation; restrain the activation of Akt, Erk, mTOR and the apoptosis of cardiomyocytes |
[9] |
||
blocking α1A adrenergic receptor |
in vitro |
rat prostate cell membrane |
/ |
/ |
[3] |